- Inspire Medical Systems ( NYSE: INSP ) said the U.S. Food and Drug Administration (FDA) approved expanding magnetic resonance imaging (MRI) scan capability to full-body for use with Inspire therapy.
- Inspire's labeling previously allowed only head, neck, and extremity MRI scans, according to the company's July 6 press release.
- The company added that the approval was retroactive — applying to all patients with the Inspire IV neurostimulator device — introduced in 2018, already in place.
- "Expanding compatible use to include full-body MRI is a significant milestone in our effort to bring Inspire to more obstructive sleep apnea patients who struggle with CPAP," said President and CEO Tim Herbert.
- Inspire therapy is an FDA approved neurostimulation technology to treat moderate to severe obstructive sleep apnea — a disorder that causes to repeatedly stop and start breathing while sleeping. A noticeable sign is snoring.
For further details see:
Inspire Medical gets full-body MRI compatibility with Inspire therapy